What a Combination Study Service Covers
Cancer vaccine and checkpoint inhibitor combination studies assess how a vaccine-based immunotherapeutic approach performs when evaluated alongside checkpoint blockade in preclinical settings. These programs are typically used by teams that want to compare combination arms against single-agent arms and vehicle controls before committing to further development. Our service supports this work as a scoped preclinical study: we help define the model and treatment arms, coordinate dosing and sample collection, run the agreed readouts, and deliver a structured report of the findings. Study parameters such as model selection, dose levels, dosing schedule, group size, and readout panel are agreed during project design, so the final scope reflects your research question rather than a fixed package.
Parallel cytokine release assays can add cytokine context to combination-treatment comparisons.
What the Service Can Include
Combination Study Design
Support in defining vaccine and checkpoint inhibitor arms, single-agent comparators, and control groups, with dosing routes and schedules agreed during scoping.
Preclinical Model Selection
Selection of immuno-oncology model systems appropriate to the combination under study, discussed and confirmed with your team before study start.
Dosing and Sample Collection
Execution of the agreed dosing schedule with scheduled sample and endpoint collection, documented against the approved study plan.
Readout and Reporting
Agreed readouts captured and summarized in a study report, with data tables and interpretation notes scoped to the parameters set at project design.
How a Combination Study Engagement Works
Typical Project Deliverables
| Deliverable | What Is Included |
|---|---|
| Study Design Summary | A written study plan covering the combination rationale, model or system selection, treatment arms, dosing schedule, and readout list, finalized with you before execution begins. |
| Combination Treatment Data | Tabulated results from vaccine and checkpoint inhibitor arms, including single-agent and combination groups where scoped, with group-level summaries suitable for internal review. |
| Immune Readout Report | Summarized assay outputs for the immune readouts selected during scoping, presented with methods notes and QC flags so results can be interpreted in context. |
| QC and Run Documentation | Records of assay controls, acceptance criteria applied, and any deviations noted during the run, provided as part of the final data package. |
| Final Study Report | A consolidated report combining design, results, and interpretation notes, formatted for internal decision-making and onward planning; raw. |
Why Teams Scope Combination Studies With Us
Combination-First Study Design
Every project is planned around the vaccine and checkpoint inhibitor pairing from the start, so treatment arms, sequencing, and readouts are defined together rather than assembled after the fact. Design decisions are documented in the study plan before work begins.
Scoped, Case-by-Case Parameters
Model selection, dosing schedule, number of arms, and readout depth are agreed per project during consultation and recorded in the statement of work. We do not push fixed packages; scope follows your question and the evidence available for your candidate.
Readouts Matched to the Question
Immune and tumor-related readouts are chosen during scoping to match what the study is meant to assess. Assay outputs are reported with methods notes and QC flags, and interpretation is framed as project-dependent rather than as a project-dependent outcome.
Further Reading
Research reference
1. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma
Nature Communications. 2023. DOI: 10.1038/s41467-023-39196-9.
View articleDiscuss Your Combination Study Design
Share your vaccine construct, checkpoint inhibitor of interest, and the questions you need answered.
Complementary tumor organoid–immune cell co-culture assays can support mechanistic follow-up in a tumor–immune co-culture setting.